Research Reports

Summary

Evofem Biosciences, Inc. entered into a Fourth Amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P., effective April 10, 2026, revising the Maturity Date of outstanding convertible promissory notes to the earlier of six months after the Effective Date, a Change of Control, or acceleration under Section 8.

Key takeaways

The Fourth Amendment resets the Maturity Date of the Notes to the earlier of (a) October 10, 2026, (b) Adjuvant’s election upon a Change of Control, or (c) acceleration under Section 8 — tightening near-term repayment timing.

Prepayment of the Notes is prohibited before October 10, 2026 without Adjuvant’s prior written consent — increasing near-term liquidity constraints.

The amendment applies to convertible promissory notes originally issued under the October 14, 2020 Securities Purchase Agreement and previously amended three times — confirming ongoing reliance on this financing facility.

Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. collectively constitute the Requisite Purchasers per Section 10.8 — affirming their controlling position in the note holder group.

Full analysis

This Fourth Amendment materially accelerates the repayment timeline for Evofem’s outstanding convertible promissory notes, establishing a hard maturity date of October 10, 2026 — just six months from the April 10, 2026 Effective Date — unless triggered earlier by a Change of Control or acceleration event. The prohibition on prepayment without Adjuvant’s consent removes flexibility to refinance or retire debt ahead of schedule, heightening near-term liquidity risk. Given that these Notes originated from a 2020 financing arrangement and have now been amended four times, the repeated modifications signal ongoing financial pressure and dependence on Adjuvant as the sole controlling creditor group. The fact that Adjuvant — acting through two affiliated funds — represents the Requisite Purchasers under Section 10.8 confirms its consolidated authority over material terms, limiting Evofem’s ability to negotiate with other stakeholders. For investors, this amendment underscores heightened refinancing risk within the next six months and reduced strategic optionality, particularly if clinical, regulatory, or commercial milestones for Evofem’s pipeline (e.g., Phexxi or future assets) are not achieved in time to support alternative capital solutions. No new funding, conversion terms, or interest rate adjustments are disclosed — the change is purely structural and temporal, intensifying near-term financial scrutiny.